Akebia Therapeutics (AKBA) Q4 2024 Annual Earnings
AKBA·Reported March 13, 2025·Before market open
Akebia Therapeutics reported Q4 2024 revenue of $46.5M, beat analyst consensus of $37.4M by $9.1M. Diluted EPS came in at $-0.10, missed the $-0.05 consensus by $0.05.
Revenue
$46.5Mbeat by $9.1M
Consensus: $37.4MDiluted EPS
$-0.10missed by $0.05
Consensus: $-0.05
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Akebia Therapeutics's Q4 2024 earnings report.
Akebia Therapeutics (AKBA) reported Q4 2024 earnings on March 13, 2025 before market open.
Akebia Therapeutics reported revenue of $46.5M and diluted EPS of $-0.10 for Q4 2024.
Revenue beat the consensus estimate of $37.4M by $9.1M. EPS missed the consensus estimate of $-0.05 by $0.05.
You can read the 10-K periodic report (0001628280-25-012470) directly on SEC EDGAR. The filing index links above go to sec.gov.